Loading stock data…
BioXcel Therapeutics (BTAI)
$1.40+0.09 (+6.87%)
After Hours$1.40+0.00 (+0.00%)· Last close Jun 29
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioXcel Therapeutics, Inc. in the Healthcare sector is trading at $1.40 with a market capitalization of $36M. Wall Street consensus targets $14.00 (4 analysts), implying a +900.0% move over the next 12 months. The stock is currently near its 52-week low of $1.01, remaining 18.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 75 is overbought against a weak tape. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +900.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 75 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $206,000↓ | $256,000↑ | $98,000↓ | $120,000↓ | $168,000 |
| Gross Profit | -$77,000↓ | $224,000↑ | $87,000↑ | $13,000↓ | $154,000 |
| Operating Income | -$10.22M↑ | -$10.28M↑ | -$14.03M↑ | -$15.85M↓ | -$10.10M |
| Net Income | -$12.69M↓ | -$12.54M↑ | -$30.91M↓ | -$19.19M↓ | -$7.25M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United Stat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$35.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
71.38%
Volume
Today's trading volume
1.10M
Recent News
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.